2011 Volume 33 Issue 6 Pages 559-563
We investigated whether renal function has an effect on risk factors for stroke and anticoagulation quality by warfarin therapy in patients with non-valvular atrial fibrillation (NVAF). Ninety-three (93) NVAF patients were enrolled and were separated into three groups according to Creatinine Clearance Rate (CCr), Group A (15 patients): <30 ml/min, Group B (23 patients): 30-50 ml/min, Group C (55 patients): >50 ml/min. We evaluated the differences in age, CHADS2 score, and time in therapeutic range (TTR) among the three groups. The averages of age, CHADS2 score, and TTR were 87.3, 3.33, and 56.9% in group A, 82.1, 3.13, and 73.5% in group B, 72.5, 2.35, and 76.8% in group C, respectively. NVAF patients with renal dysfunction had higher risks in age, higher CHADS2 score, and lower TTR. Anticoagulation therapy in NVAF patients with chronic renal dysfunction should be used carefully, taking into consideration the risk for stroke, the quality of anticoagulation, and the indication for new anticoagulants.
